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1. Introduction 
The widespread nature of protein phosphorylation/dephosphorylation underscores its key 
role in cell metabolism. Phosphate moiety balance on proteins is regulated by protein kinases 
(PK) and protein phosphatases (PP), which are milestone players of eukaryotic signaling 
pathways. In general, signaling proteins involved in intracellular pathways are transiently 
active or inactive by phosphorylation and dephosphorylation mechanisms, covalently 
executed by PK and PP, respectively (Hooft et al. 2002; Tonks, 2005). It is accepted that the 
phosphorylation state of these proteins must be kept at a dynamic equilibrium in biological 
systems. Any deviation in this balance (generally associated with augmented PK signaling) 
can cause the intracellular accumulation of serine, threonine, tyrosine-phosphorylated 
proteins, which will cause abnormal cell proliferation and differentiation, thereby resulting in 
different kinds of diseases (Souza et al., 2009). Similar deviation from this equilibrium can be 
also induced by decreased activity of protein tyrosine phosphatases (PTP) resulting from gene 
mutation or gene deletion, leading to an increase in tyrosine phosphorylated proteins in cells. 
PPs are subdivided into two major families, with regard to their physiological substrates: 
protein tyrosine phosphatases and serine/threonine phosphatases. In particular, tyrosine 
phosphorylation of key proteins is a critical event in the regulation of intracellular signaling 
pathways (Aoyama et al., 2003; Gee and Mansuy, 2004; Souza et al., 2009). There is strong 
evidence pointing that low SHP-1 PTP activity is associated with a high proliferation rate and 
an increased risk of recurrence after radical prostatectomy for localized prostate cancer 
(Tassidis et al., 2010). Moreover, it has been proposed that specific PTPs may be related to 
determining the developmental stage and aggressiveness degree of prostate cancer (Chuang et 
al, 2010). Thus, it is reasonable to suggest that the chemical modulation of PTPs may, therefore, 
be a good spot for pharmacological intervention for overcoming prostate cancer, in 
combination with conventional cancer chemotherapeutic strategies. However, the critical 
bottleneck in deciphering the role of PTPs in prostate cancer biology is the identification of 
their physiological substrates and how their enzymatic activity is related to molecular changes 
in proliferation and cell death. In this chapter we shall focus on the contribution of the low 
molecular weight protein tyrosine phosphatase (LMWPTP), Src homology 2 (SH2) domain-
containing PTP (SHP-1), cell division cycle 25 (Cdc25), acid phosphatase, phosphatase and 
tensin homolog (PTEN) and dual-specificity phosphatase (DUSP) for prostate carcinogenesis 
and describe their participation in the molecular events that lead to tumor survival and 
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osteomimetic properties, highlighting perspectives and directions for future research that 
improve current knowledge on these critical signaling molecules. 
2. Protein phosphatases 
The ubiquitous nature of protein phosphorylation/dephosphorylation underscores its key role 
in cell signaling metabolism, growth and differentiation. In fact, cells respond to internal and 
external stimuli through integrated networks of intracellular signaling pathways that act via 
cascades of sequential phosphorylation or dephosphorylation reactions which are governed by 
the action of PK and PPs, respectively (Hooft van Huijsduijnen et al., 2002; Tonks, 2005). 
PPs have been classified by structure and substrate specificity into protein serine/threonine 
phosphatases (PSTPs) and protein tyrosine phosphatases (PTPs) (Aoyama et al., 2003; Gee and 
Mansuy, 2005). 
In general, PTPs control fundamental physiological processes such as cell growth and 
differentiation, cell cycle, metabolism, immune response and cytoskeletal function. 
Furthermore, interfering with the delicate balance between counteracting PTKs and PTPs is 
involved in the development of numerous inherited and acquired human diseases such as 
autoimmunity, diabetes and cancer (Alonso et al., 2004; Andersen et al., 2004; Ferreira et al., 
2006; Souza et al., 2009; Zambuzzi et al., 2010; Zambuzzi et al., 2011). 
2.1 PTPs classification 
Up to now, 107 genes encoding PTPs have been discovered in the human genome, whereas 
81 of them have been predicted to be active PTPs (Alonso et al., 2004). Classically, PTPs were 
divided into four classes: receptor type PTPs, non-receptor PTPs, dual specificity PTPs and 
low molecular weight PTPs. However, some authors have proposed an alternative way to 
classify this enzyme family based on the amino acid residues of their catalytic domains 
(Alonso et al., 2004; Bialy and Waldmann et al., 2005). In fact, comparison of the crystal 
structure of the PTPs that have been solved to date demonstrates that the PTPs domains are 
conserved in both sequence and structure. Additionally the sequences (domains) outside the 
catalytic domain are diverse and may regulate PTP activity and/or function (Table 1).  
 Class I cysteine-based PTPs catalyze the enzymatic reaction in which an active-site 
cysteine group plays a central role and renders the PTP susceptible to oxidant agents that 
can lead to oxidation of the key cysteine and inhibition of PTP activity. This class contains 
the “classical” PTPs and the “dual specificity” protein phosphatases (DSPs), both evolved 
from a common ancestor. The “classical PTPs” members are strictly tyrosine-specific and 
according to their subcellular localization can be further divided into intracellular PTPs 
(PTP1B and SHP) and receptor-like PTPs (CD45, PTP and PTP), both containing one or 
two catalytic domain(s) of approximately 240 amino acids. The DSPs (VH1-like enzymes) 
are the most diverse group in terms of substrate specificity and can be distinguished by 
their ability to hydrolyze pSer/pThr as well as pTyr residues and non-protein substrates, 
such as inositol phospholipids. The DSP family contains, amongst others, highly 
specialized types of phosphatases. For instance, members of this family include mitogen-
activated protein kinases phosphatases (MKPs), members of the myotubularin family, 
RNA triphosphatases, and PTEN (phosphatase and tensin homologue deleted on 
chromosome 10) type phosphatase (Alonso et al., 2004; Wishart and Dixon, 2006).  
 Class II cysteine-based PTPs are especially common in bacteria and enzymes of this 
class appear to be more ancient than class I PTPs. In humans this class is represented by 
an 18 kDa tyrosine-specific low Mr phosphatase (LMPTP). LMPTP is able to 
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dephosphorylate tyrosine kinases and their substrates but its biological functions 
remain unclear. The correlation between expression and activity of variants of this PTP 
with some human diseases, including cancer, indicates that this phosphatase may be 
involved in pivotal processes in cell physiology (Malentacchi et al., 2005). 
 Class III cysteine-based PTPs are tyrosine/threonine specific phosphatases and probably 
evolved from a bacterial rhodanese-like enzyme. In humans, this class is represented by 
the group of Cdc 25 phosphatases: Cdc25A, Cdc25B and Cdc25C. These three cell cycle 
regulators act by dephosphorylation of Cdks at their inhibitory N-terminal phosphor-
Thr/Tyr motifs, a reaction that is required for the activation of these kinases to drive 
progression of the cell cycle (Hoffman et al., 2004; Kristjansdottir and Rudolph, 2004).  
 The fourth class of PTPs is represented by aspartate-based PTPs, which use a different 
catalytic mechanism with a key aspartic acid and dependence on a cation (Rayapureddi 
et al., 2003). 
 
PTP family Members 
Class I cys-based 
Receptor PTP
CD45, RPTP, RPTP, RPTP, RPTP, RPTP, RPTP, RPTP, 
RPTP, RPTP, RPTP, RPTP, DEP1, SAP1, GLEPP, PTPS31, 
PCPTP, STEP, IA2 and IA2 
Nonreceptor PTP 
PTP1B, TCPTP, PTP-MEG2, HePTP, STEP, LYP, PTP-PEST, 
PTP-HSCF, Typ-PTP and HD-PTP 
MPKs 
PAC-1, MKP1, MKP2, MKP3, MKP4, VH3, VH5, PYST2, 
MKP5, MKP7 and MK-STYX 
Atypical DSPs 
VHR, PIR1, BEDP, TMDP, MKP6, DSP20, SKRP, DSP21, 
MOSP, MGC1136, VHZ, FMDSP, VHX, VHY, HYVH1, VHP, 
Laforin, RNGTT and STYX 
PRLs 
PRL1, PRL2 and PRL3, 
CDC14s 
CDC14A, CDC14B, KAP and PTP9Q22 
Slingshots 
SSH1, SSH2 and SSH3 
PTENs 
PTEN, TPIP, TPTE, tensin and C-1-TEN 
Myotubularins 
MTM1, MTMR1, MTMR2, MTMR3, MTMR4, MTMR5, 
MTMR6, MTMR7, MTMR8, MTMR9, MTMR10, MTMR11, 
MTMR12, MTMR13 and MTMR14
Class II cys-based LMWPTP 
Class III cys-based CDC25A, CDC25B and CDC25C 
Class IV asp-based EyA1, EyA2, EyA3 and EyA4 
Alonso et al., 2004; Souza et al., 2009. 
Table 1. Classification of protein tyrosine phosphatases based on amino acid sequences of 
the catalytic domains 
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2.2 Mechanisms of PTP catalysis 
Different experimental approaches, such as X-ray crystallography, directed site mutagenesis 
and circular dichroism, have contributed to our understanding of catalysis and substrate 
recognition by PTPs. Although PTPs have conserved catalytic domains and share a common 
mechanism of action, substrate specificity of individual PTPs may display substantial 
specificity, thus resulting in these enzymes to regulate highly specialized and often 
fundamentally important processes. 
The PTP family shares a strictly conserved active site comprising the "P-loop" residues 
(H/V)C(X)5R(S/T) and a conserved acidic residue (Denu et al., 1996; Fauman et al., 1996; 
Zhang 2003; Aoyama et al., 2003). In all structurally characterized PTPs to date, the three-
dimensional structure of active-site components is also highly conserved suggesting a 
common catalytic mechanism. In general, the catalytic site is located in a groove at the protein 
surface. Its size is responsible for explaining the higher substrate selectivity of classical PTPs 
(Alonso et al., 2004). 
In vitro studies based on model substrates, such as phenyl phosphate or p-nitrophenyl 
phosphate, have provided much of the information on the mechanistic aspects of catalysis. In 
particular, it is well established that the enzyme completes its action in two major steps. In the 
first step, the phosphoryl group from the substrate is transferred to the nucleophilic cysteine, 
forming a phosphoenzyme intermediate. In the second step, this intermediate is hydrolyzed, 
leading to the regeneration of the enzyme and the release of an inorganic phosphate (Aoyama 
et al., 2003; Zhang, 1997). Although this two-step mechanism is well-established, some 
mechanistic aspects still need to be clarified, such as regulatory and inhibitory mechanisms. 
3. Protein tyrosine phosphatases and prostate cancer 
3.1 LMWPTP 
3.1.1 Signaling features 
Chernoff and Li (1985) purified a PTP from bovine heart whose characteristics were similar to 
those described for the low molecular weight acid phosphatase (See item 3.4.1). This low 
molecular weight (about 18 kDa) protein tyrosine phosphatase (LMWPTP) shares very low 
sequence homology in relation to the other protein tyrosine phosphatase families, except for 
the consensus active site motif CX5R, that contains the essential nucleophilic cysteinyl residue, 
and an identical catalytic mechanism (Tonks, 2006; Tabernero et al, 2008). All PTPs hydrolyze 
p-nitrophenylphosphate and show inhibition by vanadate, insensitivity to okadaic acid and 
lack of metal ion requirement for catalysis. LMWPTP contains two conserved adjacent 
tyrosines, Tyr131 and Tyr132, which are preferential sites for phosphorylation by protein 
tyrosine kinases and important for the regulation of its activity (Tailor et al, 1997; Buccciantini 
et al, 1999). This enzyme class is very important in cell signaling processes such as 
proliferation, adhesion and migration. It can associate with and dephosphorylate many 
growth factors and receptors, such as platelet-derived growth factor (PDGFR), fibroblast 
growth factor (FGFR), insulin receptor (IR) and ephrin receptor (Eph), causing downregulation 
of tyrosine kinase receptor functions and leading to cell division (Souza et al, 2009).  
3.1.2 Role in prostate cancer 
LMWPTP has been recognized as a positive regulator of tumor growth (Chiarugi et al., 
2004). Our research group has a long-standing interest in the possible beneficial prostate 
cancer biological effects of LMWPTP. In this scenario, we demonstrated that a compound 
www.intechopen.com
 
Prostate Cancer Dephosphorylation Atlas 
 
177 
isolated from the Chilean tree Persea nubigena and from the stem bark of Podocarpus andina 
(Podocarpaceae), modulates both expression and activity of LMWPTP in prostate cancer 
cells (PC3) which was important for diminishing the proliferation ratio of these cells (Bispo 
de Jesus et al. 2008). More recently, we observed that prostate cancer cells that had 
LMWPTP silenced showed considerable reduction in invasiveness (unpublished data). 
Thus, this enzyme is attracting great interest as a drug target. Zabell et al. (2004) described 
that specific inhibitors could be rationally designed according to each of the two isoform 
structures of this class of enzymes. Taddei et al. (2006) observed that, at least in part, the 
antitumoral activity of Aplidin could be due to the direct oxidation and inactivation of 
LMWPTP. Marzocchini et al. (2008) reported that the treatment of rats with 1,2-
dimethylhydrazine provoked a significant increase in LMWPTP expression in 
adenocarcinomas, suggesting that this phenomenon is associated with the onset of 
malignancy.  
3.2 SHP-1 
3.2.1 Signaling features 
Among all members of PTPs, SHP-1 has been suggested as a key signaling protein to control 
cell growth. Specifically, SHP-1 (an SH2 domain-containing cytosolic PTP) is an important 
modulator of intracellular phosphotyrosine level in eukaryotic cells, controlling different cell 
fates, such as proliferation, migration and differentiation through regulating signaling of 
cytokines such as IL-3R, PDGF- and EGF receptors, and other tyrosine kinase receptors 
(Tomic et al., 1995; Keilhack et al., 1998). Disruption on SHP-1 regulation can cause abnormal 
cell growth and induce different kinds of cancers such as leukemia, lymphoma, breast and 
prostate cancers as well. In order to validate this hypothesis, some authors have inserted the 
SHP-1 gene into different cancer cell lines and they reported a diminishment on growth of 
those cells (Zapata et al., 2002). Altogether, these data reinforce that SHP-1 acts as a tumor 
suppressor protein, regulating cell signaling responsible to growth of eukaryotic cells. 
3.2.2 Role in prostate cancer 
In men, it is known that androgen deprivation leads to development of a negative growth-
regulating loop involving antiproliferative molecules like somatostatin (SST) in prostate 
adenocarcinoma. Physiologically, SST presents an antiproliferative effect, impairing 
mitogenic signals upon growth factors signaling (Patel, 1999). The SST signaling starts upon 
activation of a family of transmembrane receptors (SSTRs), sharing common signaling 
pathways such as the inhibition of adenylate cyclase, activation of PTP, and modulation of 
mitogen-activated protein kinase (MAPK). A number of publications support an 
involvement of SHP- 1 on negative regulation of cellular proliferation by SST (Lahlou et al., 
2003). The expression of SHP-1 in rat prostate (Valencia et al., 1997) and in human prostate 
was shown as well (Tassidis et al., 2010). Despite the limitation of cell culture, some authors 
have defined SHP-1 as a decisive protein on determining cancer cell phenotype in vitro by 
using two classical prostate cancer cell lines: PC3 and LNCap. They determined an inverse 
relationship between cell proliferation and secreted somatostain amount. Briefly, SST was 
able to inhibit both PC-3 and LNCap cell proliferation by an autocrine/paracrine manner, 
suggesting its participation on blocking cell cycle signaling. Moreover, when SST secretion 
was blocked, the expression and activity levels of SHP-1 protein were reduced, and PC-3 cell 
proliferation was increased (Zapata et al., 2002). These authors suggest that SHP-1 could 
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play a key role in controlling prostatic cell proliferation, which also indicates that SHP-1 
expression might be a therapeutic target for treatment of prostate cancer (Zapata et al., 
2002). On the other hand, by using human prostate biopsies, Cariaga-Martinez et al. (2009) 
observed a decrease of SHP-1 and somatostatin in prostate cancer cells, and they 
demonstrated that this is consistent with aggressiveness of the tumor. In addition, Wu et 
al. (2003) proposed the diminished or abolished SHP-1 expression could be due to 
mutation of the SHP-1 gene, methylation of the promoter region or post-transcriptional 
regulation of SHP-1 protein synthesis. It might also be explained by the action of specific 
families of miRNAs. 
3.3 CDC25 
3.3.1 Signaling features 
Unbalance on either expression or activity of proteins related to control of cell cycle 
progression provokes a wide variety of malignant diseases, including prostate cancer. 
Biochemically, cell cycle progression is a well orchestrated event regulated by well-defined 
sequential activities of cyclin-dependent kinases (CDKs), cyclins, and other proteins 
(Karlsson-Rosenthal and Millar, 2006). During mitosis, Cdc2/Cyclin B complexes can be 
dephosphorylated by the CDC25 phosphatase (a dual-specificity protein tyrosine 
phosphatase). CDC25 phosphatases play a critical role in regulating cell cycle progression 
by dephosphorylating CDKs at inhibitory residues and, therefore, have been shown to 
possess oncogenic potential (Karlsson-Rosenthal and Millar, 2006). In human, CDC25 
proteins are encoded by a multigene family: CDC25A, CDC25B, and CDC25C (Turowski et 
al., 2003). It has been suggested that phosphorylation of CDC25C at Ser216 (activated Chk 
kinases) negatively regulate the activity of this phosphatase by an immediate cytoplasmic 
sequestration (Peng et al., 1997). Despite its potential role in prostate cancer, its exact 
involvement remains unclear. 
3.3.2 Role in prostate cancer 
Due to its hormone-dependent nature, prostate cancer at the metastatic stage is usually 
treated with hormone ablation therapy. Androgen receptor (AR) is a ligand-dependent 
transcription factor and its activity is regulated by numerous AR coregulators. Inadequate 
incidence of these AR coregulators contributes for the development of prostate cancer. 
Current studies have shown that AR activity is modulated by phosphorylation at specific 
sites performed by mitogen-activated protein kinases, Akt/PKB, and cAMP-activated 
protein kinase A, which control AR transcriptional activity. Guo et al. (2006) reported that 
AR was tyrosine-phosphorylated in prostate cancer cell lines and that an elevated level of 
phosphorylation was detected in hormone refractory prostate tumor xenografts, 
demonstrating that such AR modification may contribute to androgen-independent 
activation of AR. Chiu et al. (2009) demonstrated for the first time that CDC25A could 
interact with AR and inhibit its transcriptional activity. Since CDC25A overexpression is 
implicated in cancer development, their findings may provide an insight into the 
pathological role of CDC25A and AR in the development of prostate cancer. 
In addition, CDC25A phosphatase has been implicated in the regulation of Raf-1 and the 
MAPK pathway. Raf-1 controls the mitogen activated protein kinase (MAPK) pathway, 
which has been associated with the progression of prostate cancer to the more advanced and 
androgen-independent disease. Nemoto et al. (2004) showed that Raf-1 interacts with 
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CDC25A in PC-3 and LNCap cells and CDC25A inhibitors induced both extracellular signal-
regulated kinase (Erk) activation and augmented Raf-1 tyrosine phosphorylation. These 
results indicate that CDC25A phosphatase regulates Raf-1/MEK/Erk kinase activation in 
human prostate cancer cells. Indeed, CDC25A controls proliferation and survival signaling, 
culminating on modulation of prostate cancer progression and aggressiveness. 
Moreover, to determine whether CDC25C activity is altered in prostate cancer, Ozen and 
Ittman (2005) have examined the expression of CDC25C and an alternatively spliced 
variant in human prostate cancer samples and cell lines. Interestingly, they showed that 
an active dephosphorylated form of CDC25C was up-regulated in prostate cancer in 
comparison with normal prostate tissue. In addition, they showed that at the 
transcriptional level, CDC25C and alternatively spliced variants were both overexpressed 
in prostate cancer. Finally, their findings suggest that expression of the spliced variants is 
correlated with biochemical recurrence. 
Regarding CDC25B, Ngan et al. (2003) described that its overexpression is associated with 
the stage of prostate cancer, transiting from a hormone-dependent to a hormone-
independent state and contributing to prostate cancer development and progression. 
3.4 Acid phosphatase 
3.4.1 Signaling features 
Acid phosphatases (EC 3.1.3.2), enzymes that catalyze the hydrolysis of a wide range of 
orthophosphate monoesters, are largely distributed in nature and have been studied in 
numerous organisms and tissues (Granjeiro et al, 1997; Ferreira et al, 1998a, 1998b; Granjeiro 
et al, 1999; Fernandes et al, 2003; Jonsson et al, 2007). The enzyme found in mammalian 
tissues occurs in multiple forms that differ in regard to molecular mass, substrate specificity 
and sensitivity to inhibitors (Granjeiro et al, 1997). Low relative molecular mass (Mr) 
enzymes (Mr < 20.0 kDa) are insensitive to tartrate and fluoride and strongly inhibited by 
SH-reacting compounds. High Mr acid phosphatases (Mr > 100.0 kDa) are inhibited by 
tartrate and intermediary Mr enzymes (30.0 kDa < Mr<60.0 kDa) by fluoride. In contrast to 
high Mr acid phosphatases, low Mr enzymes present more restricted substrate specificity, 
preferentially hydrolyzing p-nitrophenylphosphate, flavin mononucleotide and tyrosine-
phosphorylated proteins. 
In 1985, Chernoff and Li reported several similarities between the low molecular weight 
acid phosphatase and one class of protein tyrosine phosphatase (PTP), the low molecular 
weight protein tyrosine phosphatase (LMWPTP).   
The phosphatidic acid phosphatase (PAP) is a key enzyme in both glycerolipid biosynthesis 
and cellular signal transduction. It was observed that the plasma membrane-bound type 2 
PAP, now known as lipid phosphate phosphatase, participates in germ cell migration, 
epithelial differentiation and other signaling processes (Kanoh et al, 1997; Brindley and 
Pilquil, 2009). 
3.4.2 Role in prostate cancer 
Altered acid phosphatase activities can be related to several pathological processes, such as 
those involving infectious, inflammatory or tumoral processes. For instance, high and 
intermediary molecular weight acid phosphatases levels are increased in the serum of 
patients with prostate carcinoma (Hudson et al. 1955), of patients suffering from spleen 
disorders (Kumar and Gupta, 1971), of patients with endothelial reticulum leukemia 
(Ketcham et al, 1985), etc. 
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Human prostatic acid phosphatase has been used as a valuable marker for prostate cancer, 
before the evaluation by the prostate-specific antigen (PSA). Increased prostatic acid 
phosphatase serum levels are well correlated with metastatic prostate cancer (Ahmann and 
Schifman, 1987). In normal human prostate epithelial cells, human prostatic acid 
phosphatase expression is very high and guarantees the slow proliferation rate of those 
cells (Goldfarb et al., 1986; Veeramani et al, 2005). On the other hand, decreased activity of 
this phosphatase correlates with the poor differentiation of high-grade prostate cancer. 
One possible mechanism by which this phosphatase regulates the proliferation of prostate 
cancer is due to the dephosphorylation of the receptor HER-2. Uncontrolled 
phosphorylation of HER-2 leads to increased hormone-refractory growth of prostate 
cancer cells (Chuang et al, 2010). 
3.5 PTEN 
3.5.1 Signaling features 
PTEN is a tumor suppressor protein, acting as a dual-specificity protein phosphatase. It is 
one of several enzymes with the ability to dephosphorylate tyrosine-, serine- and threonine-
phosphorylated residues (Pulido & van Huijsduijnen, 2008). It also presents lipid 
phosphatase activity, mainly towards phosphatidylinositol-3,4,5-triphosphate (Maehama & 
Dixon, 1998). This is crucial to its tumor suppressor function, since it opposes the survival 
and proliferative actions of many growth factors (Uzoh et al., 2008). 
PTEN was first described in 1997. Mutations in its encoding gene were detected, at the time, 
in several human cancer tissues and cell lines, including prostate cancer (Li et al., 1997). Its 
loss has been associated mainly with activation of the PI3K/Akt/mTOR pathway, leading to 
proliferation and survival of cancer cells (Hollander et al., 2011). 
3.5.2 Role in prostate cancer 
The lack of PTEN has been implicated in the resistance of prostate cancer cells to 
conventional chemo- and radiotherapy, as well as androgen-independence (Uzoh et al., 
2008; Huang et al., 2001; Priulla et al., 2007; Anai et al., 2006; Shen & Abate-Shen, 2007). In a 
mouse model of prostate cancer, PTEN inactivation was shown to induce growth arrest 
through the p53-dependent cellular senescence pathway both in vitro and in vivo (Chen et 
al., 2005). 
Chemo- and radiotherapy resistance is linked to overexpression of Bcl-2, an anti-apoptotic 
protein that blocks PTEN-mediated apoptosis. Huang et al. showed this overexpression to be 
related to PTEN-loss, as well as establishing an association between PTEN-induced 
chemosensitivity and inhibition of Bcl-2 expression (Huang et al., 2001). 
mTOR inhibition has also been shown to sensitize Pten-null prostate cancer cells to chemo- 
and radiotherapy (Grunwald et al., 2002; Cao et al., 2006), pointing to PTEN’s role in 
resistance. Interestingly, Cao and colleagues used an mTOR inhibitor other than rapamycin 
(RAD001 - everolimus) to enhance the cytotoxic effects of radiotherapy on two prostate 
cancer cell lines (PC-3 and DU145). They found that the increased susceptibility to radiation 
presented by both cell lines was due to autophagy, instead of apoptosis. They also showed 
that blocking apoptosis with caspase inhibition and Bax/Bak small interfering RNA leads to 
the same effects (Cao et al., 2006). TORC1/TORC2 inhibition in association with docetaxel 
and cisplatin also led to promising results in mice with chemoresistant prostate cancer 
(Gravina et al., 2011). 
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PTEN loss effects also extend to the androgen receptor (AR) activity, associated to 
androgen-independence. AR is shown to be inhibited by PTEN through blockage of the Akt 
pathway (Shen & Abate-Shen, 2007; Nan et al., 2003). However, a recent study points to the 
opposite activities of AR and PI3K signaling pathways and their cross-regulation, with 
inhibition of one activating the other, maintaining cancer cell survival by distinct means. 
Through combined pharmacological inhibition of both pathways, the authors could achieve 
near-complete prostate cancer regressions in a PTEN-deficient murine model and in human 
xenografts (Carver et al., 2011). 
Recent studies have also implicated PTEN loss in chemokine receptor 4 (CXCR4)- mediated 
prostate cancer progression and metastasis, as well as showing that reactive oxygen species 
(ROS) can increase this outcome through direct inactivation of PTEN by active site oxidation 
(Chetram et al., 2011). 
3.6 DUSP 
3.6.1 Signaling features 
Dual-specificity phosphatases (DUSPs) are enzymes able to dephosphorylate both tyrosine 
and serine/threonine residues within their substrate (Patterson et al., 2009). There are 49 
gene products characterized as human DUSPs in the Gene Ontology database (The Gene 
Ontology Consortium, 2000). These are divided into subgroups, according to their substrate 
specificity. MKPs, one of the best-characterized subgroups, are able to dephosphorylate 
mitogen-associated protein kinases (MAPKs), which are in turn increasingly implicated in 
the development and progression of several cancers, including prostate cancer. Another 
subgroup is named atypical DUSPs. Some of them also show a preference for MAPKs as 
substrates, but, unlike MKPs, they are mostly of low-molecular mass and lack the N-
terminal CH2 (Cdc25 homology 2) domain (Patterson et al., 2009). 
In spite of some clear links between some DUSPs, their substrates and specific cancer 
types, there is still variability in respect to their role in distinct tissue environments. The 
existing reports regarding prostate cancer are diverse, sometimes even antagonistic. Thus, 
the precise role of DUSPs in carcinogenesis remains to be clarified (Arnoldussen & 
Saatcioglu, 2009). 
DUSP1 is a member of the MKP group. It is able to dephosphorylate all members of the 
MAPK family, although displaying preference for p38 and JNK substrates (Magi-Galluzzi et 
al., 1997; Sun et al., 1993; Franklin & Kraft, 1997). 
DUSP3 is an atypical dual-specificity phosphatase that has controversial substrate 
specificity. ERK 1/2 and JNK were identified as direct substrates for DUSP3 (Todd et al., 1999; 
Todd et al., 2002), although a later report points to ERK2 as an unlikely substrate for DUSP3 
(Zhou et al., 2002). STAT5 was also identified as a substrate for DUSP3 (Hoyt et al., 2007). 
DUSP10 is a MKP with preference for p38 and JNK rather than ERK as substrates. It has 
been implicated in the regulation of innate and adaptive immune responses (Zhang et al., 
2004) and also has been shown to have a potent anti-inflammatory activity in prostate cells 
(Nonn et al., 2007). 
DUSP18 is a member of the atypical subgroup of dual-specificity phosphatases whose 
mRNA expression was identified in several cancer tissues and cell lines, including 
prostate, among others (Patterson et al., 2009; Wu et al., 2006). It presents phosphatase 
activity against ERK, JNK and p38 synthetic substrates, with a preference for ERK and 
JNK (Hood et al., 2002). 
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3.6.2 Role in prostate cancer 
DUSP1 mRNA was found to be overexpressed in the early phases of prostate cancer, but 
this did not prevent high ERK-1 expression (Loda et al., 1996). Overall, ERK appears to 
increase DUSP1 expression, decreasing JNK activity and inhibiting apoptosis.  In a 2008 
study it was shown that coordinate inhibition of AKT/mTOR and ERK-1/MAPK pathways 
leads to reduced cell growth and proliferation, as well as upregulation of the apoptotic 
regulator Bcl-2-interacting mediator of cell death (Bim) in a preclinical mouse model of 
hormone-refractory prostate cancer (Kinkade et al., 2008). Accordingly, a later study 
showed DUSP1 mRNA expression to be lower in hormone-refractory prostate carcinomas 
than in benign prostate hyperplasia (BPH) or untreated prostate carcinomas. Higher 
DUSP1 protein levels were found in BPH, normal prostate and high-grade prostate 
intraepithelial neoplasia (Rauhala et al., 2005). Consistent with the low levels of DUSP1 in 
response to androgen ablation, DUSP1 mRNA was found to be upregulated upon 
androgen treatment of LNCaP cells (Arnoldussen et al., 2008) The androgen receptor (AR) 
has been identified as responsible for increased expression of DUSP1 (and several other 
DUSPs) upon interaction with testosterone. However, DUSP1 implication in prostate 
cancer is not yet fully resolved, since there have been reports showing that both high and 
low levels of DUSP1 may have an antiapoptotic effect, depending on which MAP kinase 
DUSP1 is targeting (Rauhala et al., 2005). 
Similarly, androgens protect LNCaP cells from 12-O-tetradecanoylphorbol-13-acetate- and 
thapsigargin-induced apoptosis via down-regulation of JNK activity through an increase in 
DUSP3 expression. This effect was not observed in androgen-independent DU145 cells 
(Arnoldussen et al., 2008). Expression analysis in human prostate cancer specimens also 
show that DUSP3 is increased in prostate cancer compared with normal prostate, evidencing 
a direct DUSP3 role in prostate cancer progression through JNK-mediated apoptosis 
inhibition (Arnoldussen et al, 2008). 
Another DUSP that has been related to prostate cancer is DUSP10. DUSP10 presents anti-
inflammatory activity and its expression is increased after treatment with calcitriol, the 
hormonally active form of vitamin D. This results in the subsequent inhibition of p38 stress 
kinase signaling and the attenuation of the production of pro-inflammatory cytokines 
(Nonn, et al., 2006; Krishnan & Feldman, 2010). 
4. Concluding remarks 
Deciphering the molecular networks that distinguish progressive from non-progressive 
prostate cancer will bring light on the biology of this tumor, as well as lead to the 
identification of biomarkers that will aid to the selection of better-suited treatments for each 
patient. For this, it is crucial to characterize and integrate the molecular mediators involved 
in prostate cancer biology. In this chapter we pointed out some evidences of the contribution 
of protein tyrosine phosphatases for prostate cancer pathogenesis. PTPs, as a large enzyme 
family, can act as prostate cancer suppressors or promoters, depending on their target 
protein (Table 2). However, studies quantifying PTPs on gene and protein levels in prostate 
cancer have been limited. New efforts to raise this kind of combinatory data might reveal a 
spectacular relationship between genotype and PTP activity levels and lead to an 
understanding of the fundamental role of this enzyme family in controlling malignant cell 
transformation. This, in turn, may open new avenues to treat prostate cancer based on PTP 
activity modulation. 
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Phosphatase 
Prostate cancer 
cell localization 
Main action 
Main targets in prostate 
cancer 
LMWPTP cytosol cancer promoter unknown 
SHP-1 cytosol cancer suppressor 
IL-3R, PDGF- and EGF 
receptors 
CDC25B and 
CDC25C 
nucleus cancer promoter unknown 
CDC25A nucleus cancer suppressor Androgen receptor (AR) 
Acid phosphatase cytosol cancer suppressor Her-2 
PTEN 
cytosol and 
nucleus 
cancer suppressor 
phosphatidylinositol-
3,4,5-triphosphate 
DUSP nucleus cancer promoter JNK, p38 and ERK 
Table 2. Prostate cancer protein tyrosine phosphatases 
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